Laura Litwin

DocwireNews

Pembrolizumab plus chemoradiotherapy was shown to improve survival in newly diagnosed patients with high-risk, locally advanced cervical cancer (CC), according to a randomized, phase III (ENGOT-cx11/GOG-3047/KEYNOTE-A18) clinical trial <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01808-7/abstract" target="_blank" rel="noopener">published</a> in The Lancet.
Progression-free survival (PFS) was measured in the first interim analysis of the study, at which point Domenica Lorusso, MD, PhD, and colleagues found that the treatment combination resulted in a “statistically significant and clinically meaningful improvement” among patients.
In the second interim study analysis, eligible participants, patients with newly diagnosed, high-risk, (FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA regardless of nodal status) adenocarcinoma, squamous cell carcinoma, or adenosquamous CC, were assessed for overall survival (OS) by Dr. Lorusso and colleagues. OS was defined as the time from randomization to death due to any cause.
Upon randomization, patients were divided by cancer stage at screening, planned total radiotherapy dose, and planned external beam radiotherapy type. 1,060 patients across 30 countries were intravenously administered at random placebo or five cycles of pembrolizumab (200 mg) every three weeks, in addition to chemoradiotherapy, followed by 15 cycles of placebo or pembrolizumab (400 mg) every six weeks. 531 patients were in the placebo-chemotherapy cohort and 529 patients were in the pembrolizumab-chemoradiotherapy cohort.
According to the results, the 36-month OS was 74.8% (70.1-78.8) in the placebo-chemoradiotherapy group and 82.6% (95% CI 78.4-86.1) in the pembrolizumab-chemoradiotherapy group. The median OS was not reached in either group and the median follow-up for both groups was 29.9 months (interquartile range [IQR] 23.3-34.3). 371 (70%) out of 530 individuals in the placebo cohort experienced a grade 3 or higher adverse event compared to 413 (78%) out of 528 patients in the pembrolizumab cohort. The most common adverse events were decreased white blood cell count, anemia, and decreased neutrophil count, and potentially immune-mediated adverse events were observed in 90 (17%) out of 530 patients versus 206 (39%) out of 528 patients in the placebo and pembrolizumab groups, respectively. The hazard ratio for death was 0.67 (95% CI 0.50-0.90; P=.0040).
“These data, together with results from the first interim analysis, support this immune-chemoradiotherapy strategy as a new standard of care for this population,” the researchers concluded.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Study Findings Support Pembrolizumab Plus Chemoradiotherapy as New Standard of Care for Locally Advanced Cervical Cancer

Cervical Cancer

Pembrolizumab plus chemoradiotherapy was shown to improve survival in advanced cervical cancer.

Study Findings Support Pembrolizumab Plus Chemoradiotherapy for Locally Advanced Cervical Cancer

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe